OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Advances in technology are accelerating the development and manufacture of subunit vaccines.
FDA’s response to COVID-19 may impact the biologics industry long term.
Supply-chain visibility systems are proving their worth in the distribution of COVID-19 vaccines.
July 23, 2021
The EMA’s CHMP has adopted a positive opinion recommending marketing authorization for Moderna’s COVID-19 vaccine (Spikevax) to include adolescents 12 years of age and older.
July 22, 2021
Pfizer Inc. and BioNTech SE announced the signing of a letter of intent with The Biovac Institute Ltd to manufacture the Pfizer-BioNTech COVID-19 vaccine for distribution within the African Union.
July 16, 2021
ImmunityBio will proceed with a Phase I/II/III trial in South Africa of their dual-antigen T-cell vaccine as a boost in participants who were previously vaccinated against COVID-19.
July 15, 2021
EMA's PRAC has found a possible link to very rare cases of myocarditis and pericarditis after vaccination with Comirnaty and Spikevax COVID-19 vaccines.
After a review of three cases, EMA's PRAC has advised against the use of Janssen’s COVID-19 vaccine in people who have a history of capillary leak syndrome.
July 13, 2021
Moderna announces supply agreement with the Argentina government for 20 million doses of Moderna’s COVID-19 vaccine.
The IND for Tevogen Bio's TVGN-489, an allogeneic COVID-19-specific cytotoxic T lymphocyte, received rapid clearance from FDA.
July 08, 2021
Exscientia has been given funding from the COVID-19 Therapeutics Accelerator to accelerate the optimization of a new class of COVID-19 drugs created using its AI drug design platform.
The approved changes to the API manufacturing plant in Leiden, the Netherlands will enable an increase in API capacity.
July 07, 2021
An additional batch of the Janssen COVID-19 vaccine has been authorized by FDA under the Emergency Use Authorization.